Background Nicotine receptor partial agonists may help people to stop smoking by a
combination of maintaining moderate levels of dopamine to counteract withdrawal …

Interventions for smoking cessation and reduction in individuals with schizophrenia - Tsoi, DT
- 2013 | Cochrane Library Skip to Content Cookies Our site uses cookies to improve your …

Tobacco dependence is the most common substance use disorder in adults with mental
illness. The prevalence rates for tobacco dependence are two to four times higher in these …

In spite of the high association between substance use and psychiatric disorders, there is a
surprising paucity of studies related to treatment and outcome. A few well-designed studies …

Introduction The prevalence of tobacco use in the population with schizophrenia is
enormously high. Moreover, nicotine dependence is found to be associated with symptom …

Extensive evidence indicates that varenicline reduces nicotine craving and withdrawal
symptoms by modulating dopaminergic function at α4β2* nicotinic acetylcholine receptors …

Background: Cognitive deficits are amongst the most socially debilitating and least
effectively treated symptoms of schizophrenia. The cholinergic system is a promising target …

Objective: Varenicline was approved by the FDA in 2006. In 2009, based largely on case
reports, the FDA issued a warning of possible adverse neuropsychiatric effects including …

Efforts to reduce the public health burden of tobacco use have not equally benefited all
members of society, leading to disparities in tobacco use as a function of ethnicity/race …

We performed an updated meta-analysis of randomized double-blind placebo-controlled
trials (RCTs) on the effects of varenicline adjuvant therapy for smoking cessation in people …